Table 2 Efficacy of MAC regimens by direct and adjusted indirect comparison
Drug dose and study | Method of efficacy derivation | Study used for comparison | Correction factor | Adjusted monthly probability of failure | % Efficacy (95% CI) |
|---|---|---|---|---|---|
Rifabutin, 300 mg, qd | Â | Â | Â | Â | Â |
Nightingale 1993[13] | Direct | -- | -- | -- | 53 (48-61) |
Havlir 1996[17] | Adjusted indirect | Oldfield 1998 | 0.979 a | 0.014 | 44 |
Benson 2000[16] | Adjusted indirect | Pierce 1996 | 0.879 b | 0.007 | 41 |
Clarithromycin, 500 mg, bid | Â | Â | Â | Â | Â |
Pierce 1996[14] | Direct | -- | -- | -- | 66 (61-74) |
Benson 2000[16] | Adjusted indirect | Nightingale 1993 | 1.542 c | 0.007 | 73 |
Azithromycin, 1200 mg, qwk | Â | Â | Â | Â | Â |
Oldfield 1998[15] | Direct | -- | -- | -- | 66 (60-81) |
Havlir 1996[17] | Adjusted indirect | Nightingale 1993 | 0.896 d | 0.007 | 72 |